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Gamma glutamyl transferase (GGT) is a new marker for predicting myocardial infarction, stroke,
cardiac death and inflammation. There is also a strong relationship between Obstructive Sleep
ApneaSyndrome(OSAS)andcardiovasculardisease.This studywasdesigned to investigate theasso-
ciationbetweenserumGGTlevelsandcardiovasculardisease inpatientswithOSAS,and relationship
between severity of OSAS and serum GGT level. We evaluated the medical records of 166 subjects
who were admitted for sleep study. OSAS was diagnosed by polysomnography if Apnea-Hypopnea
Index (AHI)> 5.According toAHI, individuals inwhomAHI< 5were recruitedas group 1 (OSAS nega-
tive group), AHIZ 5e15: group 2 (mildOSAS group), AHIZ 15e30: group 3 (moderate OSAS group),
AHI>30: group 4 (severe OSAS group). Cardiovascular diseasewas defined if the patients had heart
failure,coronaryarterydiseaseorarrhythmia.Of thesubjects, 112 (67.5%)weremaleand themean
agewas 54.3 12.2 years. Therewere 22 patients (13.2%), 17 patients (10.2%), 34 patients (20.4%)
and 93 patients (56.2%) in group 1, 2, 3 and 4, respectively. There is a significant increase in serum
GGT levels while AHI score increases (group 1Z 28.0  10.1, group 2 Z 33.8  13.2, group
3Z 35.2 8.5, group 4Z 40.0 22.0; p for trendZ 0.024). However, serum C-reactive protein
(CRP), alanine aminotransferase and aspartate aminotransferase levels were similar in all groups
(p > 0.05). There was a significant independent association between serum GGT levels and the
severity ofOSAS.Moreover, serumGGT levelswere significantly high in patientswith cardiovascular
disease compared with patients without cardiovascular disease in severe-moderate-mild OSAS
(p< 0.05) and OSAS negative groups while CRP levels were not. This was a significant independent
association. The present study suggests that high serum GGT level, regardless of the other2 2239753.
om (A. Kanbay).
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638 A. Kanbay et al.traditional risk factors, is an independent predictor of cardiovascular disease in patientswithOSAS.
The results should be confirmed with other randomized prospective studies.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Obstructive Sleep Apnea Syndrome (OSAS) significantly
increases the risk of cardiovascular disease (CVD) including
hypertension, heart failure, arrhythmia, coronary artery
disease (CAD), stroke and diabetes mellitus.1,2 Chronic
intermittent hypoxemia is frequently encountered in
patients with OSAS and may trigger diverse pathways that
may potentially account for the health-related conse-
quences of this syndrome. Sympathetic activation, oxida-
tive stress, and metabolic dysregulation are frequently
seen in sleep apnea and may constitute etiologic mecha-
nisms, linking OSAS to cardiovascular disorders.3,4
Gamma-glutamyl transferase (GGT) is located on plasma
membranes of several cells and tissues with a predominance
of hepatocytes 5 A recent study showed that increased serum
GGT activity could be used as a marker for increased oxida-
tive stress in humans 6 In the CARDIA study, serumGGT values
were strongly and positively correlated with traditional
determinants of oxidative stress such as the levels of C-
reactive protein (CRP), uric acid, and fibrinogen 7 In the same
line, Emlin et al found that the level of GGT has an inde-
pendent predictive value for the mortality and the incidence
of non-fatal myocardial infarction in patients with a history
of myocardial infarction and documented CAD8 In a large
study of middle-aged men, the level of GGT had a prognostic
significance for overall and cardiac related mortality.9
With this background in mind, we designed this study to
investigate the association of the serum GGT level with the
severity of OSAS -defined with apnea hypopnea index (AHI)-
and cardiovascular event. We also investigated the associa-
tions between the serum level of GGT with AHI, CVD and the
levels of serum alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP), and CRP.
Material and methods
Subjects
The study population consisted of subjects recruited in the
Sleep Disorders Center of Erciyes University School of Medi-
cine between January 2005 and January 2010, who were
referred for clinically indicated sleep study. One hun-
dredsixty six patients were examined with polysomnography
(PSG). The patients were classified as OSAS negative group or
OSAS according to the AHI. Patients with an AHI < 5 were
constituted as the OSAS negative group and patients with an
AHI  5 were constituted as the OSAS group. According to
AHI, individuals in whom AHI< 5 were recruited as group 1
(OSAS negative group), AHI Z 5e15: group 2 (mild OSAS
group), AHI Z 15e30: group 3 (moderate OSAS group),
AHI> 30: group 4 (severe OSAS group). Bodymass index (BMI)
was calculated as weight in kilograms divided by the square
of height measured by a scale and BMI> 30 kg/m2 defined as
obese. Patients who had central sleep apnea syndrome,upper airway resistant syndrome, and narcolepsy or move-
ment disorder were excluded. Patients with cerebrovascular
disease or a lung disease with hypoxemia such as chronic
obstructive pulmonary diseases, interstitial lung disease,
asthma, patients with infection, patients with chronic alco-
holism, viral hepatitis, chronic liver disease, hepatobiliary
disease and elevated liver enzymes were also excluded.
Demographic characteristics, sleep, and medical history,
including cardiovascular and metabolic diseases, medication
use, and habits were obtained with the use of a standardized
questionnaire before the sleep study. Cardiovascular disease
was defined if the patients had heart failure, coronary artery
disease or arrhythmia. The demographic characteristics and
laboratory evaluation were comprised of a routine blood
examination (fasting glucose, liver enzymes, lipid profile),
respiratory function tests, electrocardiogram, and BMI. The
study was approved by the Ethics Committee of Erciyes
University and all patients signed an informed consent.
Hyperlipidemia was defined as follows: serum LDL
cholesterol > 160 mg/dl or total cholesterol > 240 mg/dl or
triglyceride > 200 mg/dl or HDL cholesterol <40 mg/dl.10
Blood pressure was measured at the non-dominant arm in
the morning of the procedure after a 5 min resting interval.
Hypertension was defined for the study purpose according to
the 2007 European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC) task force for the
management of arterial hypertension guidelines.11Polysomnography
Overnight polysomnography (PSG) was performed in all
patients with 44-channel polysomnograph (Compumedics
E series, Melbourne, Australia) at the Erciyes University Sleep
Disorders Center, and included the following variables: elec-
tro-oculogram (two channels), electroencephalogram (two
channels), electromyogram of the submental muscles (one
channel), electromyogram of the anterior tibialis muscle of
both legs (two channels); electrocardiogram and airflow (with
an oro-nasal thermistor). Chest and abdominal efforts (two
channels) were recorded using inductive plethysmography,
arterial oxyhaemoglobin saturation (SaO2: one channel) by
pulse oximetry with a finger probe. The recordings were
scored according to the standard criteria of Rechtschaffen
and Kales.12 Arousals were scored according to accepted
definitions.13 Apnea was defined as complete cessation of
airflow  10 s. Hypopnea was defined as reduction of>50% in
one of three respiratory signals, the airflow signal or either
the respiratory or abdominal signals of respiratory inductance
plethysmography, with an associated fall of  3% in oxygen
saturation or arousal.14 AHI was calculated as the number of
apneas plus hypopneas per hour of sleep. Patients with
AHI  5 events/h were diagnosed as having OSAS. The
excessive daytime sleepiness (EDS) of the patients was
assessed according to the Epworth Sleepiness Scale (ESS) and
values over 10 were accepted as pathological.15
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Serum GGT levels were measured by the enzymatic calori-
metric test at 37 C, and l-gamma-glutamyl-3-carboxy-
4-nitroanilide was used as substrate.16 To perform
that evaluation, the Roche/Hitachi analyzer (Mannheim,
Germany) was used. In our laboratory the normal reference
value of the GGT level for a healthy individual was 8e61 U/L.
Serum CRP levels were measured by the immunoturbidi-
metric method (Roche Diagnostics, GmbH, Mannheim,
Germany)with anormal reference value of less than10mg/L.
Statistical analysis
SPSS software (Statistical Package for the Social Sciences,
version 15.0, SSPS Inc, Chicago, IL, USA)was used for statistical
analyses.Thedistributionof continuous variables for normality
was tested with One-Sample KolmogoroveSmirnov test and
data are presented as mean  standard deviation (S.D.) orTable 1 Demographic and clinical characteristics of the study
OSAS negative
group (n Z 22)
Mild OSAS
(n Z 17)
Age (year) 50.7  13.9 56.8  11.
Gender (M,%) 14, 63.6% 11, 64.6%
CVD (n,%) 5, 20% 6, 33%
Polysomnographic study results
Desaturation index 3.5  1.4 3.8  0.7
Total sleep time 5:13  0:56 5:30  1:0
Sleep efficiency (%) 83.5  12.4 82.5  11.
Minimum oxygen saturation 81.3  8.5 79.1  26.
Mean oxygen saturation 92.0  2.5 90.9  4.9
Traditional risk factors for CVD
Hypertension (n,%) 5, 22.6% 5, 29.4%
Diabetes mellitus (n,%) 1, 4.5% 2, 11.7%
Smoking (n,%) 4, 18% 3, 17.6%
BMI (kg/m2) 29.3  8.5 32.4  6.2
Medications
Beta blocker use (n,%) 2, 9% 3, 17.6%
ACE inhibitor use (n,%) 2, 9% 4, 23.5%
ARB use (n,%) 1, 4.5% 2, 11.7%
Calcium antagonist
use (n,%)
1, 4.5% 1, 5.8%
Statin use (n,%) 2, 9% 2, 11.7%
Laboratory variables
CRP level (mg/dl),
(mean, median)
4.8  1.7, 6.3  3.8,
4,78 (3,22e8,68) 3,913,32
GGT level (U/L),
(mean, median (IQR))
28.0  10.1, 33.8  13.
26 (20e39) 26,5 (22,5e
AST level (U/L),
(mean, median (IQR))
24.1  7.7, 26.5  10.
22,55,19e28 255e18,18
ALT level (U/L),
(mean, median (IQR))
28.1  9.7, 26.0  9.3
22 (17,2e32,5) (19,5e28)
Abbreviations: CVD, cardiovascular disease; ACE, angiotensin conve
glutamyl transferase; CRP, C-reactive protein; AST, aspartate aminotr
IQR, interquartile range.median and interquartile ranges, as appropriate. Categorical
variables are reported as frequencies and group percentages.
Differences between patients with and without OSAS in nor-
mally and non-normally distributed variables were evaluated
by the unpaired t-test, the ManneWhitney U-test and the
KruskaleWallis respectively, as appropriate. Categorical vari-
ableswereanalyzedby thec2-test. Multiple logistic regression
analysis was used to determine the independent predictors
related to CVD in OSAS. Significant univariate variables with
P< 0.1 and traditional risk factors for CVDwere included in the
multiple logistic regression analysis for the calculation of odds
ratios and 95% confidence intervals. All P values are 2-sided,
and a P value of< 0.05 was considered significant.
Results
A total of 166 patients that satisfied the selection criteria
were included in the analysis. Demographic and biochemical
data are presented in Table 1. One hundred forty four of 166group.
Moderate OSAS
(n Z 34)
Severe OSAS
(n Z 93)
p for trend
1 54.3  13.4 54.7  11.4 NS
16, 47.1% 71, 76.3% 0.04
15, 42.9% 56, 57.7% 0.004
4.2  0.7 6.8  3.9 0.0001
5:30  1:20 5:31  1:06 NS
0 83.2  13.8 85.9  12.5 NS
0 79.1  16.2 57.6  31.2 0.0001
83.2  9.2 79.2  16.2 0.0001
12, 35.2% 34, 36.5% 0.04
4, 11.7% 11, 11.8% NS
5, 14.7% 19, 20.4% NS
31.8  6.5 33.6  6.1 NS
5, 14.7% 13, 13.9% NS
7 19, 20.4% NS
5, 14.7% 14, 15% NS
3, 8.8% 8, 8.6% NS
5, 14.7% 14, 15% NS
7.7  4.7, 8.6  4.9, NS
8,0 (3,2e12,1) 6,973,5
2, 35.2  8.5, 40.0  22.0, 0.024
42) 25 (20-35) 33,5 (24e48,2)
5, 26.7  8.7, 26.1  10.4, NS
e31 24,52,21e31 2418e31
6, 25 28.03  12.9, 30.7  17.57, NS
24 (20e39,2) 26 (19e35)
rting enzyme; ARB, angiotensin receptor blocker; GGT, gamma
ansferase; ALT, alanine aminotransferase; BMI, body mass index;
Figure 1 Serum GGT in patients with and without cardio-
vascular disease (CAD) in mild, moderate, severe OSAS patients
and OSAS negative group.
640 A. Kanbay et al.study participants were classified as having OSAS, while 22
patients with an AHI < 5 constituted the OSAS negative
group. As expected, desaturation index, minimum oxygen
saturation and mean oxygen saturation is significantly
different in each group (p for trendZ 0.0001) (Table 1).
Patients in the severe OSAS group had statistically
significant higher prevalence of CVD compared with
moderate and mild OSAS and OSAS negative groups (p for
trendZ 0.0004) (Table 1). The use of angiotensin receptor
blockers, angiotensin converting enzyme inhibitors, beta-
blockers and statins was similar in each group (p > 0.05)
(Table 1). Mean values of CRP, AST, ALT, ALP were not
different significantly between each group (p > 0.05)
(Table 1). Meanwhile, GGT values were significantly high in
the severe OSAS group compared with moderate and mild
OSAS and OSAS negative groups (p for trend Z 0.0004),
(Table 1).Although CRP levels increased while the severity
of OSAS increased, this was not statistically significant.
Serum GGT values were positively correlated with AHI
values (r Z 0. 23, p Z 0.005) but not correlated with CRP.
Moreover, serum GGT levels were significantly high in
patients with CVD compared with patients without CVD in
severe-moderate-mild OSAS and OSAS negative groups
(Fig. 1, p < 0.05 for all group).
We further divided severe and moderate OSAS group into
two groups according to median value of serum GGT values.Table 2 The prevalence of cardiovascular disease (CVD) and C-
transferase (GGT) group in severe and moderate OSAS group.
Moderate OSAS group
Low GGT group High GGT group p v
CVD (n,%) 4, 23.5% 11, 61% 0.0
CRP (mg/dl) 7.4  4.5 8.0  4.9 0.8We found that the prevalence of CVD was significantly high
in high serum GGT group compared to low serum GGT group
both in severe and moderate OSAS group (p Z 0.001 and
p Z 0.02, respectively) whereas, even serum CRP level is
high in high serum GGT group this was not statistically
significant (Table 2).
All potential determinants for the CVD were further
investigated in an univariate screening procedure (see
methods). Subsequently, all parameters related to the CVD,
with a significance level below 0.1, were introduced in
a stepwise multiple regression analysis. The final regression
model included hypertension, hyperlipidemia, diabetes
mellitus, age, and gender; the independent predictors of
CVD were serum GGT levels and hypertension in patients
with OSAS (Table 3).
Discussion
In the present study, there are 2 novel findings. First, serum
GGT levels significantly increased in a proportional manner
as the severity of OSASincreased, while serum CRP levels
were not significantly associated with OSAS. The high serum
GGT levelscould not be explained with other parameters
regarding with other disease. Second, the prevalence of
CVD is high in patients with high serum GGT levels -divided
by median value- compared with patient with low serum
GGT levels in severe-moderate-mild OSAS and patients
without OSAS.
In an animal study, it has been shown that GGT expression
is significantly increased by oxidants in rat lung epithelial cells
and it has been speculated that GGT activity might be
a marker for oxidative stress.16 Furthermore, it has been
suggested that increased serum GGTactivity could be used as
amarker of oxidative stress in humans.6,17 In the light of these
studies, many epidemiologic studies investigated the value of
serum GGT level in predicting development of diabetes mel-
litus, hypertension, CVD, mortality from all causes including
myocardial infarction, stroke and cardiac death.7e9,18e21
In the CARDIA study, the incidence of diabetes mellitus and
hypertension was significantly associated with high baseline
serum GGT levels and this association was not related with
alcohol consumption 7 Another study by Emdin et al demon-
strated that high serum GGT level is associated with cardiac
death and non-fatal myocardial infarction in patients with
documented coronary artery disease 8 In the same line, Sto-
jakovic et al investigated the relationship between GGT and
total as well as cardiovascular mortality in 2556 subjects with
and 699 subjects without angiographic evidence of CAD in the
Ludwigshafen Risk and Cardiovascular Health (LURIC) study.21
They showed that serum GGT predicts all-cause and cardio-
vascular mortality in individuals with CAD independently of
other cardiovascular risk factors.reactive protein (CRP) in high and low serum gamma glutamyl
Severe OSAS group
alue Low GGT group High GGT group p value
2 21, 42% 35, 74% 0.001
1 8.1  4.9 8.5  5.1 0.83
Table 3 Risk factors for cardiovascular diseases in patients with obstructive sleep apnea syndrome (multivariate analysis).
Odds ratio Confidence Interval 95% p value
Age (year) 1.0 0.93e1.12 0.13
Gender (Male) 1.7 0.52e2.34 0.67
GGT (U/L) 1.3 1.15e2.25 0.02
CRP (mg/dl) 1.1 0.84e1.4 0.21
BMI (kg/m2) 1.0 0.99e1.1 0.13
Hypertension 1.5 1.1e2.2 0.03
Diabetes Mellitus 1.3 0.92e1.76 0.06
Serum gamma-glutamyl transferase activity 641There is strong evidence that OSAS plays a substantial
role in the development of atherosclerosis, CAD and CVD via
promoting inflammation.22 It is well known that a significant
inflammation ea strong mediator of atherosclerosis- occurs
in OSAS patients which is shown with CRP, Interleukin- 6
(IL-6) and tumor necrosis factor-a.23 Furthermore, serum
IL-6 and CRP a potential mediator of inflammation and
atherosclerosis- levels increases in OSAS patients and are
independent predictors of CAD.24 Lee and Jacobs reported
an association between serum levels of GGT and CRP and
GGT as a marker of low-grade systemic inflammation.25 Ulus
et al. found that high serum GGT level is an independent and
better predictor than CRP for development of major
cardiovascular event in patients with acute coronary
syndromes over 1 and 6 month follow-up periods and found
a positive correlation between serum CRP and GGT levels.26
In our study, although CRP levels were high in severe OSAS
group,we did not find any significant association between
CRP and CVD in patients with OSAS which might be due to
sample size, patient selection, inclusion-exclusion criteria
of the study, whereas we found a significant association
between high serum GGT levels and CVD. To the best of our
knowledge, this is first the study that investigated the
predictive value of serum GGT levels for CVD in patients
with OSAS.
The possible mechanisms of serum GGT as a marker of
inflammation might be; i) GGT bound to LDL particles
whichmight promote atherogenesis 27, ii) GGT has been found
in atherosclerotic plaques 28,29, iii) Serum GGTwas defined as
a marker of non-alcoholic fatty liver disease (NAFLD) ewhich
is emerging as an independent cardiovascular risk factor 30, iv)
Higher serumGGT is associatedwith an increased incidence of
the metabolic syndrome 31, v) Higher serum GGT is associated
with oxidative stress which may promote atherogenesis.32
As a matter of fact, there are some limitations of our
study that we have to mention. First, this is a cross-
sectional study and the potential causal relationship
between OSAS and high serum GGT levels cannot be
concluded. Second, we did not investigate the effect of
nasal CPAP treatment on serum GGT levels. Third, we did
not followed the patients prospectively and not investi-
gated the effect of treatment of serum GGT levels
however, this study was designed for showing the associa-
tion of serum GGT levels and severity of OSAS and CVD.
The results of our study suggest that there is a strong
association between high serum GGT levelseeven in normal
limits-and cardiovascular events in patients with obstructive
sleep apnea. To better clarify that issue, further prospective
studies with great numbers are warranted.Conflict of interest
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